Literature DB >> 24129318

Prevalence of synthetic cannabinoids in blood samples from Norwegian drivers suspected of impaired driving during a seven weeks period.

Silja Skogstad Tuv1, Hege Krabseth, Ritva Karinen, Kirsten M Olsen, Elisabeth L Øiestad, Vigdis Vindenes.   

Abstract

From early year 2000 different herbal products containing synthetic cannabinoids (SC) have appeared on the drug market all over the world, and new substances are frequently introduced. The prevalence of SC use in different populations is however still mainly unknown, also in Norway. This information is difficult to obtain, but studies of drivers suspected of driving under the influence of drugs (DUID), might provide important information. The aim of this study was to assess the prevalence of SC in drivers suspected of being under the influence of drugs in Norway, and investigate if SCs impair driving performance. For two periods of three and four weeks all blood samples from drivers suspected of DUID in Norway were analyzed for the presence of 12 and 18 different SCs, respectively. A new ultra performance liquid chromatography tandem mass spectrometry method was developed. A total of 726 cases were analyzed during our study period, and SCs were detected in 16 cases (2.2%) in total. The mean age of these drivers was 29.6 years. High concentrations of other psychoactive drugs were detected in all the blood samples where a SC was found. AM-2201 and JWH-018 were the most frequently detected SCs, each found in five cases. In addition RSC-4, JWH-122, JWH-081 and JWH-250 were detected. None of the drivers had reported using SCs prior to driving. Despite the limited number of SCs investigated in this 7 week study period, a considerable percent of the cases were positive. Other psychoactive drugs of abuse were always found concomitant with the SCs, and the age of these drivers indicates that experienced drug users also ingest SCs. Since other drugs were found in all the samples, the psychomotor impairment caused by the SCs is difficult to estimate. Our study shows the importance of screening analyses of biological samples from different populations to assess the prevalence of drug use, since self-reporting might be encumbered with significant under-reporting.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AM-2201; DUID; JWH-018; Prevalence; Synthetic cannabinoids; UPLC–MS/MS

Mesh:

Substances:

Year:  2013        PMID: 24129318     DOI: 10.1016/j.aap.2013.09.009

Source DB:  PubMed          Journal:  Accid Anal Prev        ISSN: 0001-4575


  10 in total

1.  Pharmacodynamic Effects, Pharmacokinetics, and Metabolism of the Synthetic Cannabinoid AM-2201 in Male Rats.

Authors:  Jeremy Carlier; Ariane Wohlfarth; Bonita D Salmeron; Karl B Scheidweiler; Marilyn A Huestis; Michael H Baumann
Journal:  J Pharmacol Exp Ther       Date:  2018-09-28       Impact factor: 4.030

2.  Δ(9)-Tetrahydrocannabinol-like effects of novel synthetic cannabinoids in mice and rats.

Authors:  Michael B Gatch; Michael J Forster
Journal:  Psychopharmacology (Berl)       Date:  2016-02-15       Impact factor: 4.530

3.  Quantification of [1-(5-fluoropentyl)-1H-indol-3-yl](naphthalene-1-yl)methanone (AM-2201) and 13 metabolites in human and rat plasma by liquid chromatography-tandem mass spectrometry.

Authors:  Jeremy Carlier; Karl B Scheidweiler; Ariane Wohlfarth; Bonita D Salmeron; Michael H Baumann; Marilyn A Huestis
Journal:  J Chromatogr A       Date:  2016-05-06       Impact factor: 4.759

Review 4.  Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.

Authors:  Marisol S Castaneto; David A Gorelick; Nathalie A Desrosiers; Rebecca L Hartman; Sandrine Pirard; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2014-08-18       Impact factor: 4.492

Review 5.  Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health.

Authors:  Aviv M Weinstein; Paola Rosca; Liana Fattore; Edythe D London
Journal:  Front Psychiatry       Date:  2017-08-23       Impact factor: 4.157

6.  Effects of synthetic cannabinoids on psychomotor, sensory and cognitive functions relevant for safe driving.

Authors:  Vasco Orazietti; Giuseppe Basile; Raffaele Giorgetti; Arianna Giorgetti
Journal:  Front Psychiatry       Date:  2022-09-26       Impact factor: 5.435

Review 7.  Emerging drugs of abuse: current perspectives on synthetic cannabinoids.

Authors:  Danièle Debruyne; Reynald Le Boisselier
Journal:  Subst Abuse Rehabil       Date:  2015-10-20

Review 8.  Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective.

Authors:  Koby Cohen; Aviv M Weinstein
Journal:  Front Public Health       Date:  2018-06-07

Review 9.  Driving under the influence of drugs: Correlation between blood psychoactive drug concentrations and cognitive impairment. A narrative review taking into account forensic issues.

Authors:  Alberto Blandino; Rosy Cotroneo; Stefano Tambuzzi; Domenico Di Candia; Umberto Genovese; Riccardo Zoja
Journal:  Forensic Sci Int Synerg       Date:  2022-03-21

10. 

Authors:  Sarah B Windle; Crystal Sequeira; Kristian B Filion; Brett D Thombs; Pauline Reynier; Roland Grad; Carolyn Ells; Mark J Eisenberg
Journal:  CMAJ       Date:  2021-07-12       Impact factor: 8.262

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.